Sign in
SLRX Stock Price, Chart, Stats & News
Salarius Pharmaceuticals, Inc.
Save
4.92M
Market cap
–
Current P/E
–
Forward P/E
SLRX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -82.09% |
ROE | -401.03% |
D/E | – |
Interest coverage ratio | – |
SLRX valuation
P/E | – |
P/S | – |
P/B | 0.10x |
P/CF | -0.09x |
P/FCF | -1.11x |
P/OCF | -0.09x |
PEG | -0.00x |
EV multiple | -1.93x |
About
Salarius Pharmaceuticals, Inc. is a clinical-stage biotechnology firm dedicated to advancing epigenetic-based cancer therapies. Its flagship investigational product, Seclidemstat (SP-2577), a small molecule inhibitor, is currently undergoing Phase I/II clinical evaluation. This compound is being developed to treat Ewing sarcoma and a range of advanced solid tumors.
Similar securities
Based on sector and market capitalization
Report issue